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higher lifetime risk for stroke than males. Moreover, female gender has been associated with
increased ethanol consumption during adolescence. In the present study, we investigated
whether chronic ethanol exposure during adolescence may potentiate themotor impairments
and cortical damage induced by focal ischemia in female rats. We also addressed whether
these effects can be mitigated by minocycline, which has been shown to be neuroprotective
against different insults in the CNS. Female rats were treated with distilled water or ethanol
(6.5 g/kg/day, 22.5% w/v) for 55 days by gavage. Focal ischemia was induced by microinjections
of endothelin-1 (ET-1) into the motor cortex. Animals of both groups were treated daily with
minocycline (25–50mg/kg, i.p.) or sterile saline (i.p.) for 5 days, and motor function was
assessed using open ﬁeld, inclined plane and rotarod tests. Chronic ethanol exposure5
erved.
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b r a i n r e s e a r c h 1 5 6 1 ( 2 0 1 4 ) 2 3 – 3 424exacerbated locomotor activity and motor coordination impairments induced by focal
ischemia in rats. Moreover, histological analysis revealed that microinjections of ET-1 induced
pyramidal neuron loss andmicroglial activation in the motor cortex. Minocycline reversed the
observed motor impairments, microglial activation and pyramidal neuron loss in the motor
cortex of ischemic rats even in those exposed to ethanol. These results suggest that
minocycline induces neuroprotection and functional recovery in ischemic female rats
intoxicated with ethanol during adolescence. Furthermore, the mechanism underlying this
protective effect may be related to the modulation of neuroinﬂammation.
& 2014 Elsevier B.V. All rights reserved.1. Introduction
Ethanol is the most widely used drug of abuse among
adolescents due to its easy acquisition and wide acceptance
by the majority of organized societies (Sanchis and Aragón,
2007; Schuckit, 2009). Early use of this substance has been
linked to higher incidence of alcoholism in adulthood, given
that over 80% of regular drinkers reported problems related to
alcohol before the age of 30 and 40% between 15 and 19 years
of age (Chambers et al., 2003).
The high consumption of ethanol during adolescence
negatively impacts individuals, such as increased suscept-
ibility to brain damage and cognitive and behavioral disabil-
ities for both rodents and humans (Alfonso-Loeches and
Guerri, 2011). This is a critical period of central nervous
system (CNS) maturation, in which establishment of neuro-
transmission pathways and synaptic connections occur,
resulting in long-term deleterious effects of ethanol on
behavior (Crews et al., 2006; Slawecki et al., 2004; White and
Swartzwelder, 2004).
Otero Palleiro and Barbagelata López (2007) showed that
prolonged exposure to ethanol was responsible for 16% of
cases of cerebral ischemia in patients between 18 and 45
years of age. Other studies have described that consumption
of ethanol exacerbates the occurrence of cerebral ischemia in
a dose-dependent manner, contributing to poor prognosis
and failure of treatment for stroke-related symptoms (Iso
et al., 2004; Mandić and Rancić, 2011).
Stroke is among the leading causes of death in Western
countries, surpassed only by heart disease and cancer (Donnan
et al., 2008). A recent update published in the United States
reported that each year, approximately 55,000 more women than
men have a stroke. Furthermore, epidemiological studies claim
that females have a higher lifetime risk of stroke than males,
mainly among those 55–75 years of age with an incidence of 1 in
5 for women (20–21%) compared to 1 in 6 for men (14–17%)
(Go et al., 2013; Kleindorfer et al., 2010; Seshadri et al., 2006).
In addition to the high risk of stroke among females, recent
studies have shown a marked change in the ethanol consump-
tion proﬁle in females, with an early consumption during
adolescence often in a heavy binge-drinking manner (INPAD,
2013). Surprisingly, despite the evidence that ethanol exposure is
a risk factor for stroke and that females are more susceptible to
ethanol's deleterious effects especially during adolescence, there
are no studies addressing whether ethanol exposure during
adolescence exacerbates stroke-induced damage or alters treat-
ment efﬁcacy for stroke-related symptoms in female subjects.In addition to the high mortality rate, over 50% of patients
with stroke exhibit some motor impairment (Bonita, 1992).
Tissue plasminogen activator (tPA) is the only drug approved
for the treatment of acute ischemic stroke (Carpenter et al.,
2011). However, its clinical application is associated with
several limitations such as narrow therapeutic windows
(dose should be given no more than 3 h after stroke) and
the risk of hemorrhage must be ruled out (Kablau et al., 2011).
Furthermore, it has been estimated that only 6 in 1000
patients beneﬁt from this therapeutic resource (Gilligan
et al., 2005; O’Donnell et al., 2010).
Considering the paucity of approved therapies for stroke,
several studies have investigated new putative therapeutic
agents, including minocycline (Moskowitz et al., 2010; Yong
et al., 2004). Minocycline is a semi-synthetic tetracycline with
pleiotropic actions and neuroprotective effects in acute and
chronic neural disorders, including stroke (Cardoso et al., 2013;
Franco et al., 2012; Yrjanheikki et al., 1999), amyotrophic lateral
sclerosis (Gordon et al., 2008), Parkinson’s disease (Thomas and
Le, 2004), Huntington’s disease (Hodl and Bonelli, 2005), multi-
ple sclerosis (Chen et al., 2011), head trauma (Homsi et al., 2010)
and spinal cord trauma (Casha et al., 2012).
The neuroprotective effects of minocycline have been
attributed to multiple potential mechanisms (Yong et al.,
2004), but its effects on microglial activity is considered of
great importance, as neuroinﬂammation plays a pivotal role
in the pathophysiology of several CNS diseases (Block et al.,
2007; Gomes-Leal, 2012). For ischemia, minocycline has been
shown to decrease the infarct area by about 65% for the
cortex and by about 45% for the striatum following middle
cerebral artery occlusion (MCAO) (Yrjanheikki et al., 1999). We
have reported considerable neuroprotection afforded by min-
ocycline in the endotheline-1 (ET-1) model of focal ischemia
in both the cortex (Franco et al., 2012) and striatum (Cardoso
et al., 2013). Microglia activation and proliferation have been
implicated in the pathophysiology of ethanol intoxication
(Blanco and Guerri, 2007; Zhao et al., 2012). It has been shown
that a low concentration of ethanol induces an inﬂammatory
response in the CNS with the release of nitric oxide (NO) and
proinﬂammatory cytokines by microglia (Blanco and Guerri,
2007). Activation of toll-like receptors (i.e., toll-like receptors type
4 – TLR-4) and release of transcription factors (i.e., nuclear factor
kappa B – NF-κB) seem to be involved in the mechanisms of
ethanol-induced brain inﬂammation (Blanco and Guerri, 2007).
Considering that minocycline is a potent anti-inﬂamma-
tory/antibiotic tetracycline with well-established neuropro-
tective effects (Yrjanheikki et al., 1999; Franco et al., 2012;
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ment would be neuroprotective in ischemic rats chronically
intoxicated with ethanol. Moreover, considering that ethanol
exposure is a risk factor for stroke and that females are more
susceptible to ethanol's deleterious effects especially during
adolescence, in the present study we investigated whetherFig. 1 – Effects of chronic ethanol (EtOH) (6.5 g/kg/day)
administration from adolescence (35 days old) to adulthood
(90 days old) on body weight of female Wistar rats. The
results are expressed as mean7S.E.M. of body weight (g)
(n¼10 animals per group). *P≤0.05 compared to the control
group (one-way ANOVA with repeated measures, Tukey's
post-hoc test).
Fig. 2 – Effects of treatment with minocycline (MNC) on the mot
ischemia (ET-1) and chronically administered with ethanol (EtOH
as mean7S.E.M. of: (A) the total number of crossings in the open
(C) the latency to fall (s) off the rotarod (n¼10 animals per group
pretreatment; þP≤0.05 compared to the ET-1þC group of the resp
ET-1þC group of the water pretreatment (two-way ANOVA, Tukchronic ethanol exposure during adolescence may potentiate
the motor impairments and histological damage induced by
focal ischemia in female rats and whether these effects can be
mitigated by minocycline.2. Results
2.1. Effects of chronic ethanol exposure during adolescence
on body weight gain in rats
As illustrated in Fig. 1, the chronic ethanol (6.5 g/kg/day)
administration over a period of 55 days (i.e., from the 35th
day until the 90th day of life) induced a signiﬁcant reduction
in the body weight gain of rats from the 63rd to 77th days of
life (F8,128¼2.68; Po0.05). However, the ﬁnal body weight of
control- and ethanol-treated rats after the period of 55 days
of treatment did not differ statistically.
2.2. Minocycline mitigates ethanol-induced exacerbation
of locomotor activity deﬁcits and motor incoordination in
ischemic rats
The results of locomotor activity evaluated in the open ﬁeld
arena (for 5 min) are summarized in Fig. 2A. Two-way ANOVA
(pretreatment vs. treatment) revealed signiﬁcant effects foror performance of female Wistar rats subjected to focal
, 6.5 g/kg/day) during adolescence. The results are expressed
ﬁeld for 5 min; (B) the drop angle of the inclined plane; and
). *P≤0.05 compared to the control group (CþC) of the water
ective pretreatment (water or EtOH); #P≤0.05 compared to the
ey's post-hoc test).
b r a i n r e s e a r c h 1 5 6 1 ( 2 0 1 4 ) 2 3 – 3 426the main factors [pretreatment: F1,54¼10.43; Po0.01; treat-
ment: F2,54¼40.67; Po0.0001] and their interaction [F2,54¼3.58;
Po0.05]. Post-hoc comparisons indicated that ischemic ani-
mals displayed a reduced locomotor activity in the open ﬁeld
and that the chronic ethanol intoxication exacerbated these
locomotor impairments. Of high importance, post-hoc com-
parisons indicated that minocycline treatment reversed the
locomotor activity deﬁcits induced by ischemia even in the
animals intoxicated with ethanol during adolescence
(Fig. 2A).
The effects of chronic ethanol administration during
adolescence and focal motor cortex ischemia on the rats’
ability to maintain postural stability evaluated in the inclined
plane test are illustrated in Fig. 2B. Two-way ANOVA (pre-
treatment vs. treatment) revealed signiﬁcant effects for the
main factors [pretreatment: F1,54¼5.74; Po0.05; treatment:
F2,54¼82.77; Po0.0001] and their interaction [F2,54¼6.55;
Po0.01]. Subsequent Tukey's post-hoc comparisons indicated
that both ethanol exposure and focal motor cortex ischemia
induced a signiﬁcant decrease in the mean angle score when
compared to the control group (Po0.05). However, ethanol
intoxication during adolescence did not exacerbate the
impairments induced by ischemia. Remarkably, these pos-
tural stability impairments induced by ischemia and ethanol
intoxication in the inclined plane test were reversed by the
minocycline treatment (Fig. 2B).
The effects of chronic ethanol administration during
adolescence and focal motor cortex ischemia on the motor
coordination and balance of rats evaluated in the rotarod test
are illustrated in Fig. 2C. Two-way ANOVA with repeated
measures revealed no signiﬁcant effect of the pretreatment
factor [F1,54¼0.52; P¼0.47]. However, it indicated signiﬁcant
effects for the treatment [F2,54¼76.85; Po0.0001] and the
repetition factor [F2,108¼29.33; Po0.0001] and the interaction
factor between pretreatment, treatment and repetition
[F4,108¼4.59; Po0.01]. Post-hoc comparisons revealed that
focal ischemia induced a signiﬁcant decrease in the latencies
to fall in the test session 1 (T1), and that ethanol exposure
during adolescence exacerbated these impairments since
ethanol-ischemic animals displayed a poor performance in
the subsequent test session 2 (T2). More importantly, the
minocycline treatment improved the motor incoordination
induced by focal ischemia and ethanol intoxication, as
indicated by the signiﬁcant increase in the latencies to fall
in all test sessions (Fig. 2C).
2.3. Minocycline inhibits microglial activation in the motor
cortex of ischemic rats subjected to ethanol intoxication during
adolescence
The effects of minocycline treatment on microglial activation
in the motor cortex of ischemic rats treated chronically with
distilled water or during adolescence are shown in Fig. 3.
Two-way ANOVA (pretreatment vs. treatment) revealed sig-
niﬁcant effects for the main factors [pretreatment: F1,24¼7.20;
Po0.01; treatment: F2,24¼372.26; Po0.0001] and their interac-
tion [F2,24¼4.95; Po0.05] in the number of ED1þcells in
the motor cortex. Post-hoc comparisons indicated that there
was an increase in microglial activation in both ischemic
groups (distilled water or ethanol). Interestingly, ethanoladministration signiﬁcantly reduced the number of activated
macrophages by ED1þcells labeled in the motor cortex of
ischemic rats when compared to the group that received
distilled water during adolescence. More importantly, mino-
cycline treatment signiﬁcantly reduced the number of
ED1þmicroglial cells in the motor cortex of ischemic rats
even in those chronically treated with ethanol during adoles-
cence (Fig. 3).
2.4. Minocycline protects against pyramidal neuron loss in
the motor cortex of rats induced by ethanol intoxication and
focal ischemia
The effects of chronic administration of ethanol during
adolescence and focal ischemia in pyramidal cell density
analyzed by cresyl violet staining in histological sections of
the motor cortex of rats are shown in Fig. 4.
Two-way ANOVA (pretreatment vs. treatment) revealed
signiﬁcant effects for the main factors [pretreatment:
F1,16¼5.88; Po0.05; treatment: F2,16¼41.55; Po0.0001], but
not for their interaction [F2,16¼3.15; P¼0.07], in pyramidal
cell density in histological sections of the motor cortex of
rats. Subsequent Tukey's post-hoc tests indicated that micro-
injections of ET-1 induced focal infarcts with pyramidal
neuron loss in the motor cortex of rats treated with distilled
water or ethanol. The pyramidal neuron loss was reduced by
minocycline treatment in both groups.3. Discussion
In the present study, we investigated whether chronic etha-
nol exposure during adolescence inﬂuences the ischemic
outcome following ET-1-induced focal ischemia in the rat
motor cortex in female rats. In addition, we explored mino-
cycline’s effects on this experimental paradigm. The current
ﬁndings demonstrate, for the ﬁrst time, that chronic ethanol
exposure during adolescence exacerbates locomotor activity
and motor coordination impairments induced by focal ische-
mia in female rats as evaluated in the open ﬁeld and rotarod
tests, respectively. Moreover, histological analysis revealed
that microinjections of ET-1 induced focal infarcts with
pyramidal neuron loss and microglial activation in the motor
cortex of animals treated with distilled water or ethanol. Of
high importance, the treatment with minocycline reversed
the observed motor impairments, microglial activation and
pyramidal neuron loss in the motor cortex of ischemic rats
even in those chronically exposed to ethanol during
adolescence.
Previous studies have shown that ethanol intoxication
induces CNS damage, which is related to an increased inﬂam-
matory response (Blanco and Guerri, 2007; Fernandez-Lizarbe
et al., 2009; Qin and Crews, 2012a; Zhao et al., 2012). Microglia
activation seems to play an important role in the pathophy-
siology of ethanol intoxication (Fernandez-Lizarbe et al., 2009;
Qin and Crews, 2012b; Zhao et al., 2012). For instance, it has
been shown that increased expression of monocyte chemoat-
tractant protein-1 (MCP-1) and ionized calcium binding adap-
ter molecule 1 (Iba-1) is associated with microglia activation
in the brains of alcoholics (He and Crews, 2008). In addition,
Fig. 3 – Effects of treatment with minocycline (MNC) in the microglial activation analyzed by area density and activated
macrophages/microglia (ED1þ cells/mm2) in histological sections of the motor cortex of female Wistar rats subjected to focal
ischemia and chronically administered with ethanol (EtOH, 6.5 g/kg/day) during adolescence (n¼5 animals per group). Panel A
represents the control group (CþC) of the water pretreatment; Panel B represents the ischemic group (ET-1þC) of the water
pretreatment; Panel C represents the ischemic group treated with MNC (ET-1þMNC) of the water pretreatment; Panel D
represents the control group (CþC) of the EtOH pretreatment; Panel E represents the ischemic group (ET-1þC) of the EtOH
pretreatment; Panel F represents the ischemic group treated with MNC (ET-1þMNC) of the EtOH pretreatment; Panel G
represents the number of ED1þ cells per area (mm2). Arrows represent activated microglial cells. *P≤0.05 compared to the
control group (CþC) of the water pretreatment; aP≤0.05 compared to the CþC group of the respective EtOH pretreatment;
#P≤0.05 compared to the ET-1þC group of the water pretreatment; XP≤0.05 compared to ET-1þC group of the EtOH
pretreatment (two-way ANOVA, Tukey's post-hoc test). Scale¼200 lm. Inset, scale¼100 lm.
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Fig. 4 – Effects of treatment with minocycline (MNC) in the pyramidal cell density analyzed by cresyl violet staining in
histological sections of the motor cortex of female rats subjected to focal ischemia and chronically administered with ethanol
(EtOH, 6.5 g/kg/day) during adolescence. The results are expressed as mean7S.E.M. of the neuronal cell/mm2 (n¼4 animals
per group). Panel A represents the control group (CþC) of the water pretreatment; Panel B represents the ischemic group
(ET-1þC) of the water pretreatment; Panel C represents the ischemic group treated with MNC (ET-1þMNC) of the water
pretreatment; Panel D represents the control group (CþC) of the EtOH pretreatment; Panel E represents the ischemic group
(ET-1þC) of the EtOH pretreatment; Panel F represents the ischemic group treated with MNC (ET-1þMNC) of the EtOH
pretreatment; Panel G represents the number of pyramidal cells per area (mm2). Arrows represent stained pyramidal cells.
*P≤0.05 compared to the control group (CþC) of the water pretreatment; aP≤0.05 compared to the CþC group of the respective
EtOH pretreatment; #P≤0.05 compared to the ET-1þC group of the water pretreatment; XP≤0.05 compared to the ET-1þC group
of the EtOH pretreatment (two-way ANOVA, Tukey's post-hoc test). Scale¼200 lm. Inset, scale¼100 lm.
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which represent important players of ethanol-associated
neuroinﬂammation since TLR4 knockout mice do not display
neuroinﬂammation following ethanol exposure (Fernandez-
Lizarbe et al., 2009). The correlation between the neuroin-
ﬂammatory effects of ethanol and the modulation of glial
activation by minocycline has been reported (Agrawal et al.,
2011; Wu et al., 2011). These studies demonstrated that
several behavioral/functional impairments observed follow-
ing ethanol intoxication could be related to the neuroimmune
activity of glial cells, thus, minocycline emerges as a potential
therapeutic drug.
Recent in vitro (Boyadjieva and Sarkar, 2013) and in vivo
(Qin and Crews, 2012a, b; Zhao et al., 2012) studies conﬁrmed
that ethanol intoxication induces neuroinﬂammation, includ-
ing microglia activation. In such studies, ethanol induced
excessive activation of nicotinamide adenine dinucleotide
phosphate-oxidase (NADPH-oxidase) with a concomitant
increase of reactive oxygen species production and NF-κB
transcription in both experimental animals and humans (Qin
and Crews, 2012a). In addition, the same group showed that
these inﬂammatory events are related to activation of TLR,
with increased release of the tumor necrosis factor alpha
(TNF-α) and reactive oxygen species, and increased NADPH-
oxidase activity (Qin and Crews, 2012b).
In the current chronic ethanol intoxication protocol, the
observed cortical tissue damage was not directly associated
with microglia activation. Nevertheless, a modest number of
ED1þ cells were observed in the CNS parenchyma, which is
consistent with a previous study (McClain et al., 2011). In
McClain's paper, a partial activation of microglia in the
hippocampus of male Sprague–Dawley rats was observed
following binge alcohol exposure during adolescence, a phe-
nomenon that was persistent into adulthood, suggesting that
alcohol exposure during this unique developmental time
period has long-lasting consequences.
In the present study, we observed that chronic ethanol
intoxication during adolescence exacerbates the deleterious
effects of focal ischemia in locomotor activity and motor
coordination in female rats, and that minocycline partially
reversed this phenomenon. Acute ethanol intoxication
induces neurodegeneration, microglia activation and learning
and memory deﬁcits in the early days following intoxication
(Zhao et al., 2012). Our data shed light on this, by showing
that chronic ethanol intoxication during adolescence induces
tissue damage and motor impairment that are exacerbated in
the event of stroke and, more importantly, that these events
are reversed by minocycline.
The mechanisms by which minocycline affords neuropro-
tection and behavioral recovery in this experimental para-
digm remain unknown, but the possible mechanisms may
underly actions on microglia and other non-inﬂammatory-
related effects. Previous studies have demonstrated minocy-
cline as a potent anti-inﬂammatory and neuroprotective
agent (Cardoso et al., 2013; Franco et al., 2012; Hayakawa
et al., 2008; Yrjanheikki et al., 1999; Yong et al., 2004). Despite
its pleiotropic effects, inhibition of microglial activation is
considered an important mechanism of action of minocycline
(Hayakawa et al., 2008; Yrjanheikki et al., 1999; Yong et al.,
2004). On the other hand, data from in vitro rat brainhomogenate lipid peroxidation and 2,2-diphenyl-1-picrylhy-
drazyl (DPPH) radical scavenging assays show that minocy-
cline, in contrast to tetracycline, is an effective antioxidant
with radical scavenging potency similar to vitamin E (Kraus
et al., 2005). Therefore, these ﬁndings suggest that the direct
antioxidant activity of minocycline may also contribute to its
neuroprotective effects in animal models of neuronal injury.
Minocycline reduces both cortical and striatal infarct areas
up to 45% and 65% following middle cerebral artery occlusion
(MCAO) (Yrjanheikki et al., 1999). This effect was associated
with reduced microglia activation as well as neuroinﬂamma-
tion/neuroimmune response (Yrjanheikki et al., 1999;
Blandino et al., 2006). Actually, minocycline inhibited the
release of interleukin-1 beta (IL-1β) and reduced the expres-
sion of cyclooxygenase 2 (COX-2) and prostaglandin E2
(Yrjanheikki et al., 1999) in brain ischemic areas. Further-
more, minocycline also acts by anti-apoptotic mechanisms
by decreasing the release of cytochrome C frommitochondria
and other apoptotic factors into the cytoplasm, thus, pre-
venting the activation of caspase-3 and 9, which reduced cell
death by apoptosis (Zhu et al., 2002). Minocycline also
regulates the cleavage and expression of B-cell lymphoma 2
(Bcl-2), which accumulates itself in the mitochondria and
reduces the activation of the pro-apoptotic Bcl-2-like protein
4 (Bax), BH3 interacting-domain death agonist (Bid) and Bcl-2
homologous antagonist/killer (Bak) (Antonenko et al., 2010;
Grifﬁn et al., 2010). Reduction of matrix metalloproteinase
(MMP) activation by minocycline has been also described
(Brundula et al., 2002). It has been shown that minocycline
may act on the hypothalamus by decreasing the levels of
IL-1β after a stress response (footshock) (Blandino et al., 2006,
2009). Norepinephrine at adrenergic receptors appears to be
fundamental for the IL-1β response after stress, and micro-
glial inhibition by minocycline is responsible for immune
response reductions in the CNS through the activity of
noradrenergic receptors on microglia (Blandino et al., 2006).
In the CNS, the hypothalamus is a signiﬁcant site of integra-
tion for the stressor stimulus, and stress increases in corti-
costerioid levels are responsible for modulating interleukin-1
(IL-1) expression in response. Blandino et al. (2006) also
demonstrated that minocycline increases basal corticoid
levels that were not observed in the presence of stress
conditions (footshock). These authors suggest that the action
of minocycline to block the hypothalamic IL-1β response is
not a consequence of corticosteriod-mediated suppression.
On the other hand, evidence highlights that alcohol exposure
during adolescence produces long-term consequences on the
adult brain stress circuitry (Logrip et al., 2013), thus, the
alcohol protocol used in our study may contribute to the
deleterious effects of stroke observed that were reduced by
minocycline. Moreover, according to Blandino et al. (2006)
microglia may be a primary cellular source of IL-1β in the
brain during the stress response, and the authors report that
one probable mechanism of stress-induced exacerbation of
neurodegenerative disorders may be microglia activation
elicited by stressor conditions. In this sense, minocycline
emerges as a relevant drug, further by its CNS speciﬁcity,
blocking the neuroimmune response to stress exposure.
Considering that microglia activation seems to contribute
to the combined pathophysiology of stroke and ethanol
b r a i n r e s e a r c h 1 5 6 1 ( 2 0 1 4 ) 2 3 – 3 430intoxication on pyramidal cell loss, it is reasonable to sup-
pose that the beneﬁcial effects of minocycline treatment can
modulate neuronal loss related to multiple ischemic causes
and may potentially have more universal neuroprotective
applicability. Nevertheless, considering the pleiotropic effects
of minocycline, other actions may be involved and this
should be addressed in additional studies.
It must be considered that microglia activation may also be
related to neuroprotective events following stroke (Lalancette-
Hebert et al., 2007; Neumann et al., 2006, 2008) and ethanol
intoxication (Zhao et al., 2012). Following oxygen-glucose depri-
vation (OGD) in hippocampal slices, 3D two-photon microscopy
analysis revealed that microglia physically interact with neu-
rons, potentially protecting these cells from ischemic damage
(Neumann et al., 2006). The same group has shown that
microglia provide protection following ischemia by phagocyto-
sis (Neumann et al., 2008). In addition, genetic ablation of
proliferating microglia exacerbates the ischemic damage, man-
ifested by increases in pro-inﬂammatory cytokines, apoptosis
and infarct areas following experimental MCAO in mice
(Lalancette-Hebert et al., 2007).
Following ethanol intoxication, microglia may serve both
neuroprotective and detrimental actions (Zhao et al., 2012).
While in the acute phase of ethanol intoxication microglia were
shown to contribute to damage, they seem to be neuroprotec-
tive in the abstinence phase (Zhao et al., 2012). Consequently,
anti-inﬂammatory approaches must be devised to maximize
the beneﬁcial actions of neuroinﬂammation, while reducing
their detrimental effects. Complete inhibition of microglia
activation is counterintuitive in experimental models of CNS
diseases, as in the present study. It is likely that minocycline
partially performs these desirable effects (Gomes-Leal, 2012).
In conclusion, our results provide the new evidence that the
exposition of ethanol during adolescence exacerbates the motor
impairments associated with motor cortex focal ischemia. Of
signiﬁcance are the current ﬁndings indicating that minocycline
treatment improves both tissue damage and functional recovery
in ischemic female rats, including those chronically exposed to
ethanol during adolescence. The exact mechanisms involved in
the observed minocycline neuroprotective effects should be
investigated in future research, but the present data provide
promising evidence that minocycline may be useful for the
treatment of CNS damage induced by the combination of stroke
plus ethanol intoxication. It is a feasible approach considering
that minocycline is already used in the clinic for inﬂammatory
diseases (Yong et al., 2004) and has been shown to be a
promising neuroprotective drug for human stroke (Fagan et al.,
2010; Lampl et al., 2007).4. Experimental procedures
4.1. Animals
A total of 60 adolescent female (35 days old in the beginning of
the experiments) Wistar rats were obtained from the Federal
University of Pará (UFPA) and kept in collective cages (ﬁve
animals per cage). Animals were maintained in a climate-
controlled room on a 12-h reverse light/dark cycle (lights on
7:00 a.m.), with food and water ad libitum. All procedures wereapproved by the Ethics Committee on Experimental Animals of
the Federal University of Pará under license number BIO-007-09
and followed the guidelines suggested by the NIH Guide for the
Care and Use of Laboratory Animals.
4.2. Experimental groups
Animals were initially allocated to the following groups:
distilled water (n¼30) or ethanol (6.5 g/kg/day, 22.5% w/v)
(n¼30). Every day, rats were administered through orogastric
cannula over a period of 55 days (i.e., until the 90th day of life)
according to a procedure previously described (Maier and
West, 2001; Maia et al., 2009). The current protocol of ethanol
administration was based on previous studies from our
group (Maia et al., 2009) showing that ethanol intoxication
(6.5 g/kg/day) in the developing CNS may induce long-lasting
neurobehavioural impairments in rats. To investigate puta-
tive effects of ethanol intoxication on overall poor nutrition
levels that may directly affect the motor performance
cortical damage following focal ischemia, the animals’ body
weight was controlled during the entire period of ethanol
administration.
The animals were then divided into six experimental
groups (n¼10 animals per group), as follows: (i) non-
ischemic rats treated with distilled water (oral pathway,
p.o.), stereotaxically injected with sterile saline (0.9% NaCl)
and intraperitoneally (i.p.) with sterile saline; (ii) rats treated
with distilled water submitted to focal ischemia through
microinjections of endotheline-1 (ET-1) and treated with
sterile saline; (iii) rats treated with distilled water submitted
to focal ischemia and treated with minocycline (i.p.); (iv) rats
treated with ethanol (p.o.), stereotaxically injected with
sterile saline and treated with sterile saline; (v) rats treated
with ethanol submitted to focal ischemia and treated with
sterile saline; (vi) rats treated with ethanol submitted to focal
ischemia and treated with minocycline (see Fig. 5).
The animals’ survival rate in each group was assessed
throughout the entire experimental protocol period. No death
was observed within the 55 days of repeated administration
of ethanol as well as after the treatments with ET-1 and/or
minocycline (data not shown). Moreover, all the behavioral,
histopathological and immunohistochemical analyses were
performed by an experienced experimenter who was una-
ware of the experimental group of the animals tested.
4.3. Surgery and experimental model of focal ischemia
After ethanol or distilled water administration, animals were
submitted to focal ischemia through microinjections of ET-1
as described previously by Franco et al. (2012). ET-1 is a potent
vasoconstrictor decreasing about 70–80% of the local blood
ﬂow, and it is well established that ET-1 microinjections
represent a valid model of focal ischemia (Agnati et al.,
1991; Hughes et al., 2003) and is widely used by our group
(Cardoso et al., 2013; Franco et al., 2012). The animals
were anesthetized with a mixture ketamine hydrochloride
(72 mg/kg, i.p.) and xylazine (9 mg/kg, i.p.) and positioned in a
stereotaxic apparatus (model RU-336, Insights, Brazil). After
craniotomy, 40 pmol of ET-1 (Sigma-Aldrich, USA) in 1 mL of
sterile saline were injected into the left motor cortex using a
Fig. 5 – Schematic representation of the experimental design utilized in the present study.
b r a i n r e s e a r c h 1 5 6 1 ( 2 0 1 4 ) 2 3 – 3 4 31glass capillary micropipette (Sigma-Aldrich, USA). The pipette
was left in place for 5 min before being slowly withdrawn.
Control animals were injected with the same volume of
sterile saline. We used the following stereotaxic coordinates
for the ET-1 injection (in millimeters relative to bregma)
according to Paxinos and Watson (2007): 2.3 mm lateral;
1.2 mm posterior; 0.4 mm below the pial surface.
4.4. Minocycline treatment
Minocycline treatment of ischemic animals started at 2 h
post-ischemia induction and continued for the following
seven consecutive days (Fig. 5). Minocycline (Sigma-Aldrich,
USA) was administered by i.p. route at a dose of 50 mg/kg
12/12 h over 2 days after ischemia, and subsequently in a
dose of 25 mg/kg, once a day, up to the 7th day post-ischemia
(Ekdahl et al., 2003; Guimarães et al., 2010). Control animals
were i.p. injected with the same volume with sterile saline.
4.5. Open ﬁeld
The spontaneous locomotor activity of the animals was
evaluated in an open ﬁeld arena for 5 min. The apparatus,
made of wood covered with impermeable Formica, had a
white ﬂoor of 100100 cm (divided by black lines into 25
squares of 2020 cm) and white walls, 40 cm high. Each rat
was placed at the center of the open ﬁeld and the numbers of
squares crossed were registered.
4.6. Inclined plane
The animal's ability to maintain postural stability was eval-
uated with the inclined plane test. The rats were placed on
the inclined plane, which is raised in 51 increments and can
be used as an index of hindlimb strength (Murphy et al.,
1995). The maximum inclination at which the rat could
maintain its position for 5 s was recorded as the ﬁnal angle.Each rat was tested in ﬁve consecutive trials with an inter-
trial interval of 60 s, and the average angle was calculated.
4.7. Rotarod
The rotarod apparatus (Insights, Brazil) consists of a grooved
metal roller (8 cm in diameter) and separated 9-cm wide
compartments elevated 16 cm. As a part of the test proce-
dure, animals were initially trained to maintain themselves
on the rotating rod at 15 rpm for a period of more than 3 min
(habituation phase). Subsequently, after a period of 24 h, the
animals were evaluated for their ability to remain on the
rotating rod for three successive trials of 3 min each (Sharma
et al., 2009).
4.8. Histopathological and immunohistochemistry
analyses
The lesion area was visualized in coronal sections (20- and
50-μm thick) stained with cresyl violet. The site of ET-1
injection was recognized by the presence of colanyl blue
and through the tissue pallor associated with the loss of cell
bodies. In order to analyze both pyramidal neuron density
and microglial activation, we resorted to standard stained
and immunohistochemical procedures, respectively. The
density of pyramidal neurons was evaluated in 50-mm sec-
tions stained with cresyl violet. Neurons were recognized by
the presence of their visible nuclei displaying a pyramidal
morphology. Activated microglia/macrophages were labeled
using the antibody ED1 (1:500, Serotec, UK), which binds to an
epitope on the lysosomal membrane of activated macro-
phages and microglia.
The immunohistochemical procedures are described in
detail in our previous study (Gomes-Leal et al., 2005). Brieﬂy,
the slide-mounted sections were removed from the freezer,
kept in an oven at 37 1C for 30 min and rinsed in 0.1 M
phosphate buffer saline (PBS) for 5 min. In order to improve
labeling intensity, sections were treated with 0.2 M boric acid
40X
10X
Fig. 6 – Schematic representation of the count in the motor cortex lesion area.
b r a i n r e s e a r c h 1 5 6 1 ( 2 0 1 4 ) 2 3 – 3 432(pH 9.0) previously heated to 65 1C for 25 min. This tempera-
ture was maintained constant over the treatment period.
Sections were allowed to cool down for about 20 min and
incubated under constant agitation in an 1% hydrogen per-
oxide solution in methanol for 20 min. Sections were then
rinsed in 0.05% PBS/Tween (Sigma Company, USA) solution
for 5 min for three times and incubated with 10% normal
horse serum in PBS for 1 h. Without further rinsing, sections
were then incubated overnight with the primary antibody in
PBS, rinsed in PBS/Tween solution for 5 min (three times), and
incubated with biotinylated horse anti-mouse (ED1 antibody)
secondary antibodies (Vector Laboratories, USA) diluted 1:500
in PBS for 2 h. As a negative control, normal serum, rather
than primary antibody, were used in some sections. Sections
were rinsed again for 5 min (three times) and incubated in the
avidin–biotin–peroxidase complex (ABC Kit, Vector Labora-
tories, USA) for 2 h. Sections were rinsed four times (5 min
each) and revealed with 3,30-diaminobenzidine (DAB)
(Gomes-Leal et al., 2005). After the DAB reaction, sections
were rinsed two times (5 min each) in 0.1 M PB, dehydrated,
and coverslipped with Entellan (Merck, Germany).
4.9. Qualitative and quantitative analyses
All sections were initially surveyed by light microscopy.
Illustrative images from all experimental groups were
obtained with a digital camera (Moticam 2500) attached to a
microscope (Nikon, Eclipse 50i). We used coronal sections
containing the damaged motor cortex to count the numbers
of pyramidal cells and activated macrophages/microglia
(ED1þcells/mm2) using a 0.0665-mm2 square graticule
attached to the microscope eyepiece (objective 40 ). We
counted three ﬁelds per section and three sections per animal
for all experimental groups. The regions of interest had the
highest cell density along a line passing through the lesion
center (central ﬁeld), and two additional ﬁelds were chosen at
1-mm intervals (1 mm medially and 1 mm laterally) (Fig. 6)
(Schnell et al., 1999).4.10. Statistical analysis
All values are expressed as means7S.E.M. (n¼10 animals per
group for behavioral tests and n¼4–5 per group for histolo-
gical analyses). Statistical comparison of body weight gain
between control and ethanol groups was performed using
one-way analysis of variance (ANOVA) with repeated mea-
sures (days). Data from rotarod tests were evaluated with
two-way ANOVA (pretreatment vs. treatment) with repeated
measures (trials). The rest of the data was compared using
two-way ANOVA with pretreatment (water vs. ethanol) and
treatment (control vs. ET-1 vs. ET-1 plus minocycline) as
independent variables. Following signiﬁcant ANOVAs, multi-
ple post-hoc comparisons were performed using Tukey's test.
The accepted level of signiﬁcance was Po0.05. All tests were
performed using the Statistica software package (StatSoft
Inc., Tulsa, OK, USA).Authors contribution
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